32 results
8-K
EX-99.1
TSVT
2seventy bio, Inc.
5 Apr 24
Regulation FD Disclosure
9:22am
% for Abecma in the commercial setting. Abecma was recently approved in Japan, Switzerland and the European Union for adult patients with triple-class
8-K
EX-99.1
TSVT
2seventy bio, Inc.
18 Mar 24
Departure of Directors or Certain Officers
7:04am
, Co-Promotion, and Profit Share Agreement between Bristol Myers Squibb and 2seventy bio. Abecma is also approved in the European Union, Switzerland
8-K
EX-99.1
61fqz59bl4i92
5 Feb 24
Bristol Myers Squibb and 2seventy bio Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple
7:02am
8-K
EX-99.2
iv9caluc8hktld7gu
12 Dec 23
Regulation FD Disclosure
7:25am
PRE 14A
1p5lc55aal3mlnw
18 Apr 23
Preliminary proxy
5:21pm
8-K
EX-99.1
bqtnpc9kp cdqh
17 Apr 23
Other Events
7:36am
8-K
EX-1.1
ae21 bxgjjkutq1kf
18 Nov 22
Entry into a Material Definitive Agreement
4:40pm
8-K
EX-99.1
8l3ogyjbagjt
10 Aug 22
Other Events
12:00am
DEF 14A
qonwviw5 jnhe8dsw
26 Apr 22
Definitive proxy
4:11pm
10-K
6c1lzydgqceaz31e
22 Mar 22
Annual report
7:09am
8-K
EX-99.2
8q1e9
11 Jan 22
Results of Operations and Financial Condition
7:29am
8-K
EX-99.1
frp9z
14 Dec 21
2seventy bio Presents Data Across Multiple Cell Therapy Programs at ASH 2021 Annual Meeting
7:36am
10-Q
6f4nk2o9ce
1 Dec 21
Quarterly report
7:08am
8-K
EX-99.1
4tt9rxoo
4 Nov 21
2seventy bio to Present Data from its Portfolio of Oncology Cell Therapies at the 63rd
4:51pm
8-K
EX-99.2
3xn230v8qakfx lmvv
4 Nov 21
Entry into a Material Definitive Agreement
7:24am